If You Invested in Bionoid Pharma Inc (BINP)
Looking for the live price? See the BINP quote & overviewWhat $1,000 or $10,000 in BINP Would Be Worth Today
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jul 10, 2015 |
|---|---|---|---|---|
| $1,000 | $1,000 +0% | $7 -99% | $4 -100% | $1 -100% |
| $10,000 | $10,000 +0% | $66 -99% | $38 -100% | $14 -100% |
Based on real historical closing prices through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for BINP$1,000 Investment Over Time
BINP vs S&P 500Year-by-Year Returns
BINP annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2016 | $20.00 | $10.00 | -50.0% | -50.0% |
| 2017 | $10.00 | $8.00 | -20.0% | -60.0% |
| 2018 | $8.00 | $12.50 | +56.3% | -37.5% |
| 2019 | $12.50 | $6.50 | -48.0% | -67.5% |
| 2020 | $6.50 | $5.75 | -11.5% | -71.3% |
| 2021 | $5.75 | $0.37 | -93.6% | -98.1% |
| 2022 | $0.37 | $1.25 | +237.8% | -93.8% |
| 2023 | $1.23 | $1.00 | -18.7% | -95.0% |
| 2024 | $1.00 | $0.31 | -69.2% | -98.5% |
| 2025 | $0.26 | $0.04 | -85.1% | -99.8% |
About Bionoid Pharma Inc
Healthcare · OTC Link
BIONOID PHARMA INC (OTC: BINP), now operating as AI Maverick Intel Inc. following a corporate rebranding, is a growth-focused company centered on artificial intelligence and digital engagement. According to company disclosures, its strategy emphasizes acquiring revenue-generating businesses and applying its proprietary AI Maverick platform to enhance customer interaction, operational efficiency, and user experience across multiple sectors.
The company has confirmed that the State of Delaware approved its formal name change from Bionoid Pharma Inc. to AI Maverick Intel Inc., with the new name effective as of April 30, 2025. It has also submitted the necessary filings with FINRA to update its name and trading symbol on the OTC Markets. While the BINP ticker remains in use on the OTC Pink market, the business is described as an AI-first operator with a focus on technology-driven growth.
Business Focus and Strategy
Company materials describe Bionoid Pharma Inc./AI Maverick Intel Inc. as a forward-thinking organization that uses artificial intelligence to unlock commercial opportunities and improve digital engagement. Its roadmap highlights growth through acquisitions, particularly of revenue-positive e-commerce websites and other revenue-generating businesses. These acquired operations are intended to be integrated with the AI Maverick platform to support scalable automation and data-driven engagement.
The AI Maverick platform is characterized as a versatile, AI-powered system that supports intelligent customer interaction, dynamic communication, and data-driven engagement. It is positioned as a foundation for innovation across sectors such as health and wellness, healthcare, biotech, insurance, transportation, and other verticals where targeted outreach and customer acquisition are central.
AI Maverick Platform and Prospecting Engine
Company news releases describe the AI Maverick platform as enabling intelligent, two-way engagement and AI-powered prospecting. The platform aggregates large volumes of structured and unstructured data into unified contact profiles, surfacing elements such as job changes, buying signals, and personal preferences in real time. It uses adaptive language models to determine the appropriate channel, timing, and tone for each message, supporting both transactional and consultative sales processes.
An enhanced prospecting engine has been rolled out that allows revenue teams to research, engage, and qualify prospects at scale without adding headcount. The platform is described as handling discovery questions, objections, and next-step scheduling, functions that are traditionally performed by sales development representatives or experienced sales personnel. It is also presented as capable of managing quotes, renewals, and re-orders, as well as conducting needs analysis, solution-fit discussions, and personalized recommendations through multi-step AI-driven dialogues.
Sector Coverage and Use Cases
Across its communications, the company highlights applications in sectors including healthcare, biotech, insurance, transportation, and the broader health and wellness space. In these areas, AI Maverick Intel aims to automate early-stage customer interactions, streamline outreach, and reduce friction in the sales funnel. The company states that its automation-first model is intended to support faster deal cycles, reduced acquisition costs, and tailored user experiences for clients and end customers.
Within e-commerce, particularly in health and wellness, the company’s strategy includes acquiring revenue-generating websites and using its AI Maverick Intel marketing system to enhance engagement and advertising efficiency. The platform is described as supporting intelligent customer interaction tools and dynamic communication systems that can be adapted to different business models and verticals.
Corporate Evolution and Rebranding
Bionoid Pharma Inc. has outlined a transformation from its prior identity into AI Maverick Intel Inc. as part of a strategic shift toward AI-driven innovation. The rebranding is linked to the acquisition of the AI Maverick Intel platform and a stated vision of becoming a significant participant in the AI ecosystem. The company characterizes this evolution as more than a name change, describing it as a move to align its public identity with a focus on artificial intelligence, scalable automation, and strategic business combinations.
Earlier company communications also reference a focus on the health and wellness sector and revenue-generating e-commerce acquisitions, with the AI Maverick Intel platform described as central to marketing and engagement efforts. Over time, the narrative has expanded to emphasize broader AI-in-marketing and AI-led prospecting capabilities across multiple industries.
Capital Markets and Governance
The company’s common shares trade on the OTC Pink market under the symbol BINP. It has announced the submission of an application to uplist from the OTC Pink to the OTCQB Venture Market, a process that involves review of financials, governance, and disclosures by OTC Markets Group. Company statements link this effort to goals of enhanced market visibility, liquidity, and trading efficiency, while emphasizing a commitment to transparency and financial governance.
To support these objectives, Bionoid Pharma Inc./AI Maverick Intel Inc. has engaged PCAOB-registered accounting firms to conduct audits of its financial statements for multiple fiscal years. The completion of audits for earlier years and the engagement of auditors for subsequent periods are presented as key steps in strengthening financial reporting and regulatory compliance.
Position in the AI and Digital Engagement Space
In its public communications, the company positions itself within the rapidly expanding AI-in-marketing and AI-led sales engagement segments. It emphasizes automation, intelligent engagement, and data-driven decision-making as core themes. By combining an acquisition strategy with the deployment of its proprietary AI Maverick platform, the company aims to build long-term value, attract strategic partners, and establish a defined role in the broader AI ecosystem.
Overall, Bionoid Pharma Inc., operating as AI Maverick Intel Inc., presents itself as an AI-focused enterprise that integrates artificial intelligence into customer acquisition, digital engagement, and revenue operations for its own business and for clients across multiple sectors.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Bionoid Pharma Inc investment returns
How much would $1,000 invested in Bionoid Pharma Inc be worth today?
If you invested $1,000 in Bionoid Pharma Inc (BINP) 10 years ago on 2016-07-11, your investment would be worth $4 today, representing a -99.6% total return, growing at a compounded rate of -45.2% per year (CAGR).
Has Bionoid Pharma Inc outperformed the S&P 500?
Over the past 10 years, BINP returned -99.6% compared to +249.3% for the S&P 500, underperforming the benchmark by 348.9 percentage points.
What is Bionoid Pharma Inc's average annual return?
The compound annual growth rate (CAGR) of BINP over the past 10 years is -45.2%, growing at a compounded rate each year. Individual years vary significantly — BINP's best recent year was 2022 (+237.8%) and worst was 2021 (-93.6%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
